Advertisement
Table 1 Mean or number (%). Range (Min-Max) and ANOVA of demographic and clinical baseline characteristics of groups
| Characteristic | Groups | |||
|---|---|---|---|---|
| Total (n = 40) | Experimental (n = 20) | Control (n = 20) | F (p) | |
| Age (yr). mean (Range) | 66.30 (50–82) | 67.80 (50–82) | 64.80 (54–81) | 0.95 (0.33) |
| Marital Status. number (%) | ||||
| Single | 5 (12.5) | 3 (15) | 2 (10) | |
| Married | 19 (47.5) | 14 (70) | 5 (25) | |
| Divorced/Separated | 6 (15) | 0 (0) | 6 (30) | |
| Widow | 10 (25) | 3 (15) | 7 (35) | |
| Education level. Number (%) | ||||
| Any study | 11 (27.5) | 7 (35) | 4 (20) | |
| Primary/ Secondary School | 16 (40) | 7 (35) | 9 (45) | |
| Vocational training/ Qualifications | 8 (20) | 3 (15) | 5 (25) | |
| University/ Superior education | 5 (12.5) | 3 (15) | 2 (10) | |
| Employed. number (%) | 9 (22.5) | 3 (15) | 6 (30) | |
| Weight (Kg). mean. (Range)* | 72.98 (44–130) | 72.71 (53.2–97) | 73.25 (44–130) | 0.01 (0.91) |
| Height (cm). mean. (Range)* | 159.60 (147–171) | 159.25 (148–170) | 159.95 (147–171) | 0.11 (0.74) |
| Body Mass Index (BMI). mean. (Range) | 28.17 (16.17–47.79) | 28.80 (20.70–39.91) | 28.62 (16.17–47.79) | 0.01 (0.92) |
| Overweight (BMI ≥ 25). number (%) | 30 (75) | 14 (70) | 16 (80) | |
| Waist perimeter (cm.). mean. (Range) | 97.63 (68–147) | 95.80 (75–120) | 99.45 (68–147) | 0.69 (0.41) |
| Hip perimeter (cm). mean. (Range) | 110.19 (89–145) | 111.85 (93–130) | 108.53 (89–145) | 0.72 (0.40) |
| Tumor grade. Number (%) | ||||
| Grade I | 8 (20) | 6 (30) | 2 (10) | |
| Grade II | 16 (40) | 9 (45) | 7 (35) | |
| Grade III | 14 (35) | 5 (25) | 9 (45) | |
| Grade IV | 2 (5) | 0 (0) | 2 (10) | |
| Kind of treatments. Number (%) | ||||
| Surgery (S) | 3 (7.5) | 3 (15) | 0 (0) | |
| S+ Chemotherapy (ChT) | 3 (7.5) | 0 (0) | 3 (15) | |
| S+ Radiotherapy (RT) | 15 (37.5) | 10 (50) | 5 (25) | |
| S+ ChT+ RT | 19 (47.5) | 7 (35) | 12 (60) | |
| Previous Tamoxifen (TMX). number (%) | 9 (22.5) | 3 (15) | 6 (30) | |
| TMX treatment duration (mo). mean. (Range) | 4.46 (0–32) | 4.30 (0–32) | 4.64 (0–25) | 0.01 (0.91) |
| Aromatase Inhibitors (AIs). number (%) | ||||
| Anastrozole (Arimidex®) | 12 (30) | 4 (20) | 8 (40) | |
| Letrozole (Femara®) | 23 (57.5) | 14 (70) | 9 (45) | |
| Exemestane (Aromasin®) | 5 (12.5) | 2 (10) | 3 (15) | |
| AIs treatment duration (mo). mean. (Range) | 17.40 (2–52) | 15.25 (2–52) | 19.55 (2–44) | 1.25 (0.27) |
| Comorbidities. number (%) | ||||
| Cervical pain | 33 (82.5) | 19 (95) | 14 (70) | |
| Shoulder pain | 34 (85) | 18 (90) | 16 (80) | |
| Lumbar pain | 30 (75) | 17 (85) | 13 (65) | |
| Hands/ Wrist pain | 25 (62.5) | 12 (60) | 13 (65) | |
| Hypertension | 24 (60) | 14 (70) | 10 (50) | |
| Heart disease | 8 (20) | 3 (15) | 5 (25) | |
| Circulation problems | 23 (57.5) | 12 (60) | 11 (55) | |
| Thyroid problems | 6 (15) | 4 (20) | 2 (10) | |
| Stroke | 0 (0) | 0 (0) | 0 (0) | |
| Diabetes | 5 (12.5) | 2 (10) | 3 (15) | |
| Gastric/ duodenal ulcer | 1 (2.5) | 0 (0) | 1 (5) | |
| Breathing problems | 6 (15) | 2 (10) | 4 (20) | |
| Parkinson | 0 (0) | 0 (0) | 0 (0) | |
| Cognitive impairment | 0 (0) | 0 (0) | 0 (0) | |
| Migraine/chronic headache | 7 (17.5) | 4 (20) | 3 (15) | |
| Vision problems | 13 (32.5) | 7 (35) | 6 (30) | |
| Hearing problems | 10 (25) | 6 (30) | 4 (20) | |
| Lymphedema | 4 (10) | 2 (10) | 2 (10) | |
